What we cover
Pharmacology
Treatment-resistant depression, ketamine, psychedelic-assisted therapy regulatory paths, and the safety frame each demands.
Digital therapeutics
Reimbursed digital interventions, prescription apps, and the evidence bar regulators are settling on.
Diagnosis
Diagnostic frameworks under revision, biomarker work in mood and psychotic disorders, and the implications for trial enrichment.
Access & system
Workforce, insurance parity, and the structural reasons that mental healthcare so often does not reach the people who need it.
Latest signals
See all →Adolescent depression care widens past SSRI defaults
Esketamine adolescent indication consideration, ECT and TMS adolescent access, structured measurement-based care, and integrated school-and-medical models are reshaping adolescent depression care.
Treatment-resistant schizophrenia care formalises around clozapine integration
Clozapine pathway formalisation, KarXT muscarinic mechanism integration, and emerging mechanism-targeted programs are reshaping treatment-resistant schizophrenia.
Cannabis use disorder pharmacotherapy programs reach late-stage trials
Late-stage cannabis use disorder pharmacotherapy programs and integrated behavioural-and-pharmacological care models are emerging in a previously bare category.
Snapshots
See all →Treatment-resistant schizophrenia therapy reference (2026)
Reference snapshot of TRS therapy across clozapine, augmentation, and emerging mechanism tiers.
Autism spectrum disorder care reference (2026)
Reference snapshot of ASD care across behavioural therapy, educational support, pharmacotherapy for associated symptoms, and emerging core-symptom programs.
Tobacco use disorder therapy reference (2026)
Reference snapshot of tobacco use disorder therapy across pharmacotherapy, behavioural support, and integrated care models.
Explained
See all →What is treatment-resistant schizophrenia?
Plain-language primer on treatment-resistant schizophrenia, why clozapine matters, and what comprehensive care looks like.
Autism spectrum disorder care explained
Plain-language primer on ASD care, why it is multidisciplinary, and what is changing in pharmacotherapy.
What is tobacco use disorder?
Plain-language primer on tobacco use disorder, why quitting is difficult, and what the modern combined approach can offer.
Continue reading
Full intelligence on PanaceaIntel
PatientSpotlight publishes the headline framing. The full brief, the editorial takeaway, and the source list sit on PanaceaIntel for entitled clients.
New to PanaceaIntel? Request access and the team will reply within one working day.